EMPG:NASDAQEmpro Group Inc. Analysis
Data as of 2026-03-31 - not real-time
$17.36
Latest Price
7/10Risk
Risk Level: Medium
Executive Summary
Empro Group Inc. trades at a staggering PE ratio of 193, far above the healthcare distribution industry average of 25, while a discounted cash‑flow model suggests a fair value of only $0.24 versus the current price of $17.36. The stock is technically overbought with an RSI of 71 and a bearish MACD histogram, and it is perched on a flat support/resistance line at $17.36, indicating limited upside momentum. Despite impressive revenue growth of 141% and strong operating margins (36% operating, 62% gross), the company carries a near‑100% debt‑to‑equity ratio, negative free cash flow, and a modest market cap of $143 M, raising concerns about financial sustainability.
Given the low beta (0.33) and near‑zero recent volatility, price movements appear muted, but thin trading volume creates liquidity risk. In this context, the stock appears significantly overvalued with substantial downside risk, making a cautious stance prudent across time horizons.
Given the low beta (0.33) and near‑zero recent volatility, price movements appear muted, but thin trading volume creates liquidity risk. In this context, the stock appears significantly overvalued with substantial downside risk, making a cautious stance prudent across time horizons.
Market Outlook
Short Term
< 1 yearCautious
Model confidence: 8/10
Key Factors
- Extreme overvaluation relative to peers
- Bearish MACD and overbought RSI
- Negative free cash flow and high debt load
Medium Term
1–3 yearsNeutral
Model confidence: 6/10
Key Factors
- Robust revenue growth and strong operating margins
- Continued financial strain from debt and cash flow deficits
- Potential price correction to more realistic valuation levels
Long Term
> 3 yearsPositive
Model confidence: 5/10
Key Factors
- Fundamental upside if the company can deleverage and generate cash
- High ROE indicating efficient use of equity
- Opportunity to acquire shares at a steep discount to DCF fair value
Key Metrics & Analysis
Financial Health
Revenue Growth141.60%
Profit Margin13.70%
P/E Ratio192.9
ROE66.26%
ROA16.42%
Debt/Equity99.92
P/B Ratio17.1
Op. Cash Flow$129.7K
Free Cash Flow$-205317
Industry P/E25.5
Technical Analysis
TrendNeutral
RSI71.4
Support$17.36
Resistance$17.36
MA 20$17.36
MA 50$17.36
MA 200$14.18
MACDBearish
VolumeStable
Fear & Greed Index72.7
Valuation
Fair Value$0.24
GradeOvervalued
TypeGrowth
Risk Assessment
Beta0.33
0Sector RiskMedium
Reg. RiskMedium
Geo RiskMedium
Currency RiskLow
Liquidity RiskHigh
Similar Tickers
This analysis may contain inaccuracies and is provided for informational and research purposes only. It is not personal investment advice, a recommendation, or an instruction to buy, sell, or hold any asset.